4//SEC Filing
Trius Therapeutics Inc 4
Accession 0001209191-13-044236
CIK 0001356857operating
Filed
Sep 12, 8:00 PM ET
Accepted
Sep 13, 7:15 PM ET
Size
18.4 KB
Accession
0001209191-13-044236
Insider Transaction Report
Form 4
Prokocimer Philippe
Chief Medical Officer
Transactions
- Disposition to Issuer
Common Stock
2013-09-11−82,022→ 0 total(indirect: By Trust) - Disposition to Issuer
Stock Option (right to buy)
2013-09-11$12.21/sh−1,744$21,294→ 0 totalExercise: $1.29Exp: 2019-01-08→ Common Stock (1,744 underlying) - Disposition to Issuer
Stock Option (right to buy)
2013-09-11$10.00/sh−50,000$500,000→ 0 totalExercise: $3.50Exp: 2020-11-02→ Common Stock (50,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2013-09-11$12.21/sh−16,569$202,307→ 0 totalExercise: $1.29Exp: 2018-05-20→ Common Stock (16,569 underlying) - Disposition to Issuer
Stock Option (right to buy)
2013-09-11$7.37/sh−150,000$1,105,500→ 0 totalExercise: $6.13Exp: 2023-03-06→ Common Stock (150,000 underlying) - Disposition to Issuer
Common Stock
2013-09-11−12,190→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2013-09-11$8.70/sh−90,000$783,000→ 0 totalExercise: $4.80Exp: 2022-03-07→ Common Stock (90,000 underlying)
Footnotes (3)
- [F1]Includes 1,325 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on 9/10/13.
- [F2]Pursuant the terms of that certain Agreement and Plan of Merger, dated as of July 30, 2013, by and among Trius Therapeutics, Inc., Cubist Pharmaceuticals, Inc., and BRGO Corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Trius common stock was validly tendered for $13.50 per share in cash plus one non-transferrable contingent value right for each share (each a "CVR"), which represents the contractual right to receive up to $2.00 per share upon the achievement of certain milestones, subject to any required withholding of taxes.
- [F3]Pursuant the terms of the Merger Agreement and the Offer, each stock option that was outstanding and unexercised as of the Offer Acceptance Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive $13.50 per share (minus the exercise price of the option) in cash plus one CVR which represents the contractual right to receive up to $2.00 per share upon the achievement of certain milestones, subject to any required withholding of taxes.
Documents
Issuer
Trius Therapeutics Inc
CIK 0001356857
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001356857
Filing Metadata
- Form type
- 4
- Filed
- Sep 12, 8:00 PM ET
- Accepted
- Sep 13, 7:15 PM ET
- Size
- 18.4 KB